Target Corporation to Webcast 2nd Quarter Earnings Conference Call on Wednesday, August 21, 2024
Target Corporation to Webcast 2nd Quarter Earnings Conference Call on Wednesday, August 21, 2024
PR Newswire
MINNEAPOLIS, Aug. 20, 2024
MINNEAPOLIS, Aug. 20, 2024 /PRNewswire/ --
WHAT: | Target Corporation's (NYSE:TGT) webcast of its second quarter earnings conference call. |
WHEN: | Wednesday, August 21, 2024 - 7:00 a.m. central time |
HOW: | Investors and the media are invited to listen to the call through the company's website at Corporate.Target.com/Investors (click on the link under "Events & Presentations") |
WHO: | Minneapolis-based Target Corporation (NYSE: TGT) serves guests at nearly 2,000 stores and at Target.com, with the purpose of helping all families discover the joy of everyday life. Since 1946, Target has given 5% of its profit to communities, which today equals millions of dollars a week. Additional company information can be found by visiting the corporate website and press center. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/target-corporation-to-webcast-2nd-quarter-earnings-conference-call-on-wednesday-august-21-2024-302225761.html
SOURCE Target Corporation
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks